Back to Search
Start Over
Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2ArAcute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study
- Source :
- Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 2 pLBA-5-LBA-5
- Publication Year :
- 2023
-
Abstract
- Background: Most patients (pts) with histone-lysine N-methyltransferase 2A (KMT2A)-rearranged (KMT2Ar) acute leukemia, relapse after conventional chemotherapy and hematopoietic stem cell transplant (HSCT). Remission rates after relapse (complete remission [CR], 5%) and median overall survival (2.4 mo) in ≥2nd salvage therapies in adults remain low (Blood Cancer J. 2021;11[9]:162). In KMT2Arleukemia, interaction of menin with KMT2A fusion proteins is a key driver of leukemogenesis. However, no therapies targeting the menin-KMT2A interaction have been approved. Revumenib (SNDX-5613; rev), a small-molecule inhibitor of menin-KMT2A interactions, demonstrated preliminary efficacy and safety in a phase 1 study of R/R KMT2Arand nucleophosmin 1-mutated (NPM1m) acute leukemias. We report topline efficacy and safety for pts with R/R KMT2Aracute leukemia treated with rev in a pivotal phase 2 study (AUGMENT-101; NCT04065399).
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 142
- Issue :
- 1, Number 1 Supplement 2
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs64785095
- Full Text :
- https://doi.org/10.1182/blood-2023-192042